Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Change in Account Payables (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Change in Account Payables for 8 consecutive years, with -$2.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 557.59% year-over-year to -$2.7 million, compared with a TTM value of -$3.5 million through Sep 2025, down 897.97%, and an annual FY2024 reading of -$286000.0, down 123.18% over the prior year.
  • Change in Account Payables was -$2.7 million for Q3 2025 at X4 Pharmaceuticals, up from -$3.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $3.9 million in Q4 2022 and bottomed at -$3.4 million in Q2 2025.
  • Average Change in Account Payables over 5 years is $100947.4, with a median of $4000.0 recorded in 2024.
  • The sharpest move saw Change in Account Payables crashed 3000.0% in 2022, then skyrocketed 61800.0% in 2025.
  • Year by year, Change in Account Payables stood at $1.9 million in 2021, then skyrocketed by 109.89% to $3.9 million in 2022, then plummeted by 79.31% to $808000.0 in 2023, then tumbled by 90.35% to $78000.0 in 2024, then plummeted by 3502.56% to -$2.7 million in 2025.
  • Business Quant data shows Change in Account Payables for XFOR at -$2.7 million in Q3 2025, -$3.4 million in Q2 2025, and $2.5 million in Q1 2025.